Trials / Completed
CompletedNCT02731131
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
A Randomized, Pilot, Open-Label, Monocenter, Efficacy and Safety Study Examining the Effects of Peginterferon Alfa-2a (Pegasys) With or Without Ribavirin (Copegus) in Patients With Chronic Hepatitis D
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection. |
| DRUG | Ribavirin | Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses. |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2016-04-07
- Last updated
- 2016-07-15
- Results posted
- 2016-07-15
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02731131. Inclusion in this directory is not an endorsement.